Kohei shitara (@KoheiShitara) / X

Kohei shitara on X: This was fantastic experience at @sloan_kettering. It was also my great pleasure to invite @YJanjigianMD to Japan. Lets keep global collaboration and friendships! / X

Kohei shitara (@KoheiShitara) / X

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

Raghav Sundar (@sundar__raghav) / X

Dr. Shitara on Zolbetuximab Plus mFOLFOX6 in CLDN18.2+, HER2– Gastric/GEJ Adenocarcinoma

Joseph J Zhao (@josephjzhao) / X

Kohei shitara (@KoheiShitara) / X

Kohei shitara (@KoheiShitara) / X

Kohei Shitara, MD, Discusses Immunotherapy in Gastric Cancer at 2022 IGCC

Kohei shitara on X: Nivolumab monotherapy two dose as NAC for gastric cancer showed 5 patients (16%) with MPR(<10% tumor) including 4 MSI-H and 1 MSS patients. Supporting ongoing perioperative trials.#stomachcancer @OncoAlert

Kohei SHITARA, Chief, Department of Gastrointestinal Oncolology

Kohei SHITARA, Chief, Department of Gastrointestinal Oncolology